AIRS Medical

The company's core product is SwiftMR™, a software solution that employs deep learning algorithms to enhance the quality of magnetic resonance imaging (MRI) scans. A key feature of SwiftMR™ is its ability to reduce MRI scan times by up to 50% without compromising image clarity. This is achieved by taking accelerated, lower-quality scans and using AI to denoise and sharpen them into high-resolution images. The technology is compatible with all MRI scanner vendors, models, and ages, eliminating the need for costly hardware upgrades. The software can be deployed via the cloud or on-premise, offering flexibility for healthcare institutions. By increasing patient throughput, the technology presents a clear value proposition to its clients, which include hospitals and diagnostic imaging centers. AIRS Medical primarily generates revenue through a subscription-based or pay-per-use model for SwiftMR™.

A significant milestone for AIRS Medical was winning the fastMRI Challenge, hosted by Facebook AI Research and NYU Langone Health, in both 2019 and 2020, which validated the capabilities of their image reconstruction algorithms. The company has secured substantial funding, including a $20 million Series C round in July 2024, bringing its total funding to $44.5 million. SwiftMR™ launched commercially in South Korea in late 2021 and has since expanded into international markets, including the United States and Europe, which now account for over half of the company's annual recurring revenue. The product has received regulatory clearances in numerous regions, including FDA 510(k) in the U.S., CE mark certification in Europe, and approval in Japan.